SG10201704963TA - Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy - Google Patents

Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy

Info

Publication number
SG10201704963TA
SG10201704963TA SG10201704963TA SG10201704963TA SG10201704963TA SG 10201704963T A SG10201704963T A SG 10201704963TA SG 10201704963T A SG10201704963T A SG 10201704963TA SG 10201704963T A SG10201704963T A SG 10201704963TA SG 10201704963T A SG10201704963T A SG 10201704963TA
Authority
SG
Singapore
Prior art keywords
gpc3
targeting drug
administered
patient responsive
drug therapy
Prior art date
Application number
SG10201704963TA
Other languages
English (en)
Inventor
Toshihiko Ohtomo
Jun Amano
Mikiko Nakamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201704963TA publication Critical patent/SG10201704963TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201704963TA 2012-12-21 2013-12-24 Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy SG10201704963TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012280304 2012-12-21

Publications (1)

Publication Number Publication Date
SG10201704963TA true SG10201704963TA (en) 2017-07-28

Family

ID=50978006

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504604WA SG11201504604WA (en) 2012-12-21 2013-12-24 Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
SG10201704963TA SG10201704963TA (en) 2012-12-21 2013-12-24 Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201504604WA SG11201504604WA (en) 2012-12-21 2013-12-24 Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy

Country Status (15)

Country Link
US (2) US10782300B2 (fr)
EP (1) EP2937697B1 (fr)
JP (2) JP6359461B2 (fr)
KR (1) KR102216345B1 (fr)
CN (2) CN104871003B (fr)
AR (1) AR094269A1 (fr)
AU (1) AU2013365430B2 (fr)
CA (1) CA2895333A1 (fr)
HK (1) HK1208910A1 (fr)
IL (1) IL239488B (fr)
MX (1) MX2015007714A (fr)
RU (1) RU2707882C2 (fr)
SG (2) SG11201504604WA (fr)
TW (1) TWI693073B (fr)
WO (1) WO2014097648A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2015170480A1 (fr) * 2014-05-08 2015-11-12 中外製薬株式会社 Agent thérapeutique ciblant le gpc3 pour administration à des patients pour qui la thérapie par agent thérapeutique ciblant le gpc3 est efficace
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA3116265A1 (fr) 2014-10-07 2016-04-14 Cytlimic Inc. Peptide derive de hsp70, et procede de fabrication de composition pharmaceutique, inducteur d'immunite, et cellule presentatrice d'antigene permettant le traitement ou la prevention du cancer l'utilisant
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
RU2714117C2 (ru) * 2015-03-09 2020-02-11 Ситлимик Инк. Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток
EP3797794A1 (fr) 2015-04-07 2021-03-31 Cytlimic Inc. Médicament comprenant un agoniste au recepteur toll like 3 et une proteine lag-3
WO2017002934A1 (fr) * 2015-07-01 2017-01-05 中外製薬株式会社 Agent thérapeutique à gpc3 ciblé administré à un patient dans lequel un agent thérapeutiques à gpc3 ciblé est déterminé comme étant efficace
CN106397593B (zh) * 2015-08-03 2019-09-10 科济生物医药（上海）有限公司 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
EP3153230A1 (fr) * 2015-10-08 2017-04-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Procédé de production de membranes poly (méthyle méthacrylate) (pmma) et leurs utilisations
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
CN105759051B (zh) * 2016-02-25 2018-12-18 广州科方生物技术股份有限公司 一种磷脂酰肌醇蛋白聚糖-3的定量分析试剂盒及其制备方法
US10577609B2 (en) * 2016-03-07 2020-03-03 Postech Academy—Industry Foundation Glypican-3 specific aptamer and use thereof
WO2017159699A1 (fr) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Procédés de traitement de cancers au moyen d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-gpc3
WO2018070069A1 (fr) 2016-10-11 2018-04-19 サイトリミック株式会社 Médicament
TWI780102B (zh) 2017-01-10 2022-10-11 國立大學法人山口大學 抗gpc3抗體
AU2018279278A1 (en) * 2017-06-05 2019-12-19 Janssen Biotech, Inc. Methods of engineering surface charge for bispecific antibody production
WO2019059411A1 (fr) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha Posologie pour polythérapie utilisant des antagonistes de liaison d'axe pd-1 et un agent de ciblage gpc3
WO2020089769A1 (fr) * 2018-10-29 2020-05-07 Janssen Biotech, Inc. Anticorps se liant spécifiquement à un complexe hla-dr/colii_259 et leurs utilisations
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
CN113444179B (zh) * 2020-03-26 2022-09-02 苏州普乐康医药科技有限公司 一种抗gpc3抗体和包含该抗体的药物组合物
WO2022171100A1 (fr) * 2021-02-10 2022-08-18 江苏先声药业有限公司 Anticorps gpc3 humanisé et son utilisation
WO2022197949A2 (fr) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Compositions de protéines de fusion chimériques modifiées et leurs méthodes d'utilisation
WO2022268196A1 (fr) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 Protéine de liaison à un antigène ciblant gpc3
CN113817055B (zh) * 2021-10-27 2023-04-18 福州迈新生物技术开发有限公司 抗Actin蛋白单克隆抗体、细胞系及其应用
MX2024005926A (es) 2021-11-16 2024-06-04 Sotio Biotech Inc Tratamiento de pacientes con liposarcoma mixoide/de celulas redondas.
WO2023174401A1 (fr) * 2022-03-18 2023-09-21 映恩生物制药（苏州）有限公司 Conjugué anticorps anti-gpc3-médicament et son utilisation
WO2024097998A1 (fr) * 2022-11-04 2024-05-10 Foundation Medicine, Inc. Biomarqueurs immunitaires composites et leurs utilisations

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
WO1996004925A1 (fr) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US6436411B1 (en) * 2000-10-23 2002-08-20 The Center For The Improvement Of Human Functioning, Int'l., Inc. Cancer treatment method
AU2002226930A1 (en) 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
PT1411118E (pt) 2001-06-22 2008-12-09 Chugai Pharmaceutical Co Ltd Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60326567D1 (de) 2002-05-23 2009-04-23 Sunnybrook & Womens College Diagnose von hepatozellulärem karzinom
WO2004023145A1 (fr) * 2002-09-04 2004-03-18 Perseus Proteomics Inc. Procede de detection du cancer par detection du gpc3
WO2004022595A1 (fr) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Elaboration d'un anticorps utilisant une souris mrl/1pr
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
EP2364996B1 (fr) 2002-09-27 2016-11-09 Xencor Inc. Variantes FC optimisées et leurs procédés de génération
ES2542885T3 (es) 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
WO2005070963A1 (fr) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Variants de la region fc
JP4658926B2 (ja) * 2004-04-28 2011-03-23 株式会社ペルセウスプロテオミクス 肝癌治療後の再発予測判定薬
JP4331227B2 (ja) * 2004-07-09 2009-09-16 中外製薬株式会社 抗グリピカン３抗体
NZ579543A (en) * 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
EP2213683B1 (fr) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Régions Fc variantes
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
WO2006022407A1 (fr) * 2004-08-24 2006-03-02 Chugai Seiyaku Kabushiki Kaisha Thérapie adjuvante utilisant des anticorps anti-glypicane 3
US20080003623A1 (en) 2004-10-05 2008-01-03 Atsushi Nakajima Monitoring Agent for Seriousness of Hepatitis
AU2005297772B2 (en) 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
CA2587766A1 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2007005612A2 (fr) 2005-07-01 2007-01-11 Medimmune, Inc. Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
WO2007021841A2 (fr) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et procedes d'utilisation de ces anticorps
JP2007093274A (ja) * 2005-09-27 2007-04-12 Perseus Proteomics Inc 癌の診断方法および治療薬
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
CA2631184A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
US7723043B2 (en) 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
WO2007137170A2 (fr) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Conjugués médicamenteux d'anticorps anti-glypicane-3
DE602007013068D1 (de) 2006-09-13 2011-04-21 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
EP2174938A1 (fr) 2006-10-12 2010-04-14 SuperGen, Inc. Derivés quinolines pour modulation de la méthylation du RNA
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
NZ584769A (en) 2007-09-28 2011-09-30 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
EP4269443A3 (fr) 2007-12-26 2023-12-27 Xencor, Inc. Variants fc avec liaison altérée à fcrn
AU2009226423B2 (en) 2008-03-17 2014-11-27 Chugai Seiyaku Kabushiki Kaisha Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CN101377506A (zh) * 2008-04-16 2009-03-04 北京科美东雅生物技术有限公司 磷脂酰肌醇蛋白聚糖-3化学发光免疫分析测定试剂盒及其制备方法
EP2277044B1 (fr) 2008-05-13 2015-06-17 Genentech, Inc. Analyse de conjugués anticorps-médicaments utilisant capture par affinite à base de billes et spectrométrie de masse
US9079957B2 (en) * 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
WO2011057034A2 (fr) * 2009-11-05 2011-05-12 Sloan Kettering Institute For Cancer Research Catenae : cellules souches cancéreuses des séreuses
CN102276721B (zh) 2010-06-12 2013-12-25 上海市肿瘤研究所 一种用于肝癌血清学诊断的单克隆抗体及其用途
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US9206257B2 (en) * 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2013070468A1 (fr) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Anticorps spécifique de glypican-3 et ses utilisations
CN113527469A (zh) 2012-02-09 2021-10-22 中外制药株式会社 抗体的Fc区变异体
CA2860369A1 (fr) 2012-03-02 2013-09-06 Roche Glycart Ag Biomarqueur predictif pour le traitement du cancer avec des anticorps actives par adcc
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CA2876916A1 (fr) 2012-06-18 2013-12-27 National Cancer Center Kit permettant de diagnostiquer un melanome malin
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
JP5876012B2 (ja) * 2013-07-25 2016-03-02 株式会社スギノマシン 継手

Also Published As

Publication number Publication date
AU2013365430B2 (en) 2019-10-31
JPWO2015097928A1 (ja) 2017-03-23
CA2895333A1 (fr) 2014-06-26
EP2937697B1 (fr) 2019-07-03
HK1208910A1 (en) 2016-03-18
IL239488A0 (en) 2015-08-31
TW201436805A (zh) 2014-10-01
JPWO2014097648A1 (ja) 2017-01-12
JP6359461B2 (ja) 2018-07-18
CN111060687A (zh) 2020-04-24
MX2015007714A (es) 2015-09-07
SG11201504604WA (en) 2015-07-30
EP2937697A4 (fr) 2016-07-13
CN104871003B (zh) 2019-12-20
NZ707774A (en) 2020-10-30
RU2015129697A (ru) 2017-01-26
US10782300B2 (en) 2020-09-22
WO2014097648A1 (fr) 2014-06-26
IL239488B (en) 2020-08-31
TWI693073B (zh) 2020-05-11
AR094269A1 (es) 2015-07-22
JP6484562B2 (ja) 2019-03-13
US10451627B2 (en) 2019-10-22
RU2707882C2 (ru) 2019-12-02
US20150285806A1 (en) 2015-10-08
CN104871003A (zh) 2015-08-26
AU2013365430A1 (en) 2015-05-21
KR20150096384A (ko) 2015-08-24
EP2937697A1 (fr) 2015-10-28
KR102216345B1 (ko) 2021-02-17
US20170010270A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
IL239488B (en) A gpc3-targeted medicinal agent administered to a patient who responds to treatment with a gpc3-targeted medicinal agent
SG11201609014TA (en) Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
HK1258394A1 (zh) 治療劑傳遞
HK1206937A1 (en) Methods of administering pirfenidone therapy
EP2827869A4 (fr) Compositions et procédés d'amélioration du bénéfice thérapeutique de l'indirubine et de ses analogues y compris du mésoindigo
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
PL2941257T3 (pl) Terapia choroby z zastosowaniem tolerogennego preparatu farmaceutycznego
GB201207543D0 (en) Treatment of transfusion blood
ZA201502332B (en) Medicinal treatment of dermal diseases in companion animals with norketotifen
HK1205450A1 (en) Medicine comprising combination of general anesthetic drug and hydrogen
HK1202827A1 (zh) 改進型藥物輸送裝置
HK1203847A1 (en) Fixed dose combination therapy of parkinsons disease
PT3046537T (pt) Preparação farmacêutica de hidratos de carbono para utilização terapêutica
GB201112739D0 (en) Production and administration of therapeutic agents
UA24885S (uk) Карта-калькулятор дозувань медичних препаратів